Actinium Pharmaceuticals, Inc.
ATNM
$1.52
-$0.03-1.94%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | 80.00% | -10.00% |
| Total Revenue | -- | -- | -- | 80.00% | -10.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | 80.00% | -10.00% |
| SG&A Expenses | 43.75% | -9.41% | -21.99% | -24.38% | -10.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.70% | -19.00% | -14.81% | -3.25% | 23.14% |
| Operating Income | 1.54% | 18.87% | 14.96% | 3.33% | -23.22% |
| Income Before Tax | 2.02% | 21.66% | 18.40% | 8.02% | -19.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.02% | 21.66% | 18.40% | 8.02% | -19.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.02% | 21.66% | 18.40% | 8.02% | -19.33% |
| EBIT | 1.54% | 18.87% | 14.96% | 3.33% | -23.22% |
| EBITDA | 1.50% | 19.14% | 15.18% | 3.36% | -23.48% |
| EPS Basic | 14.35% | 30.75% | 26.95% | 15.77% | -10.92% |
| Normalized Basic EPS | 14.37% | 30.76% | 26.94% | 15.75% | -10.95% |
| EPS Diluted | 14.35% | 30.75% | 26.95% | 15.77% | -10.92% |
| Normalized Diluted EPS | 14.37% | 30.76% | 26.94% | 15.75% | -10.95% |
| Average Basic Shares Outstanding | 13.80% | 13.03% | 11.51% | 9.66% | 8.50% |
| Average Diluted Shares Outstanding | 13.80% | 13.03% | 11.51% | 9.66% | 8.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |